What Is Plavix?
PLAVIX (Clopidogrel) is a prescription medicine that when taken daily can help reduce your risk of having a future heart attack or stroke. It is recommended for people who have suffered from a recent heart attack or recent stroke, or who have been diagnosed with peripheral artery disease, or P.A.D.—poor circulation in the legs that may cause pain during exercise, such as walking, and may be relieved by rest.
PLAVIX, taken with aspirin, is also recommended for people who have been hospitalized with heart-related chest pain or had a certain type of heart attack (non–Q-wave MI)—conditions doctors call Acute Coronary Syndrome (ACS).
PLAVIX helps keep platelets in the blood from sticking together and forming clots, which helps keep your blood flowing. This helps protect you from a future heart attack or stroke.
Plavix Side Effects
Clopidogrel (Plavix) plus low-dose aspirin reduces cardiovascular events and deaths in patients with vascular disease compared with aspirin alone, a new study confirms. The study, which clarifies when to use dual antiplatelet therapy, reveals that Plavix (clopidogrel) does not provide the same benefit for patients with risk factors but no documented disease.
The CHARISMA (clopidogrel - Plavix - for high atherothrombotic risk and ischemic stabilization management and avoidance) study randomised 15,603 patients with previous cardiovascular or peripheral arterial disease or multiple risk factors to daily clopidogrel (Plavix) (75 mg) or placebo, plus aspirin (75–162mg). Results were reported at the American College of Cardiology annual scientific session in Atlanta, Georgia, this week and online in The New England Journal of Medicine (12 March).
They show the rate of myocardial infarction, stroke, or death from cardiovascular causes in the subgroup of more than 12,000 patients with established vascular disease was reduced by 12.5 per cent (6.9 per cent with clopidogrel versus 7.9 per cent with placebo; P=0.046) after a median follow-up of 28 months. However, patients with risk factors but no documented disease showed no reduction, with a trend to increased risk of events (6.6 per cent with clopidogrel versus 5.5 per cent with placebo; P=0.20). This dichotomy meant that results for the entire group did not reach significance (6.8 per cent versus 7.3 per cent; P=0.22).
The lead investigator, Deepak Bhatt, Cleveland Clinic, Ohio, said: “The findings confirmed previous studies showing benefit with clopidogrel plus aspirin in patients with symptomatic atherothrombosis but showed the potential harm outweighed the benefit in those who only had risk factors.”
In 2003 the FDA required label changes to the Plavix patient information insert stating that Plavix increased the risk of intracranial bleeding, GI (gastrointestinal bleeding), ulcerative colitis, lycophytic colitis, strokes, and heart attacks.
-
PLAVIX is contraindicated in patients with active pathologic bleeding such as peptic ulcer or intracranial hemorrhage. PLAVIX should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or coadministration with NSAIDs or warfarin.
-
As part of the worldwide post marketing experience with PLAVIX, there have been cases of reported thrombotic thrombocytopenic purpura (TTP), some with fatal outcome. TTP has been reported rarely following use of PLAVIX, sometimes after a short exposure (<2 weeks). TTP is a serious condition that can be fatal and requires urgent treatment including plasmapheresis (plasma exchange).
-
In clinical trials, the most common clinically important side effects were pruritus, purpura, diarrhea, and rash; infrequent events included intracranial hemorrhage (0.4 percent) and severe neutropenia (0.05 percent).

If you or a loved one have have taken Plavix - Clopidogrel - and have experienced any of the Plavix side effects listed above you may be entitled to compensation. For more information regarding the Plavix litigation or a possible Plavix class action lawsuit contact our Plavix Lawyer today.
Click here for a free Plavix case evaluation.
|
02/06/2008 - Patients treated for heart attack or angina and given the anticlotting drug Plavix had a sharply increased rate of death or heart attack within 90 days after being taken off the drug, researchers found. More>>>
10/1/2007- Several whistleblowers provided confidential information to the United States Department of Justice which resulted in a $515 million taxpayer recovery against the drug company Bristol Myers to settle health care fraud allegations. More>>>
10/31/2006 - The first personal injury lawsuit against the makers of Plavix, Bristol-Myers Squibb and Sanofi-Aventis, has been filed. More >>>
04/12/2006 - People taking the blood thinner Plavix on top of aspirin to try to prevent heart attacks, as many doctors recommend, now have good reason to stop.. More >>>
|